Compare · BIOC vs ELV
BIOC vs ELV
Side-by-side comparison of Biocept Inc. (BIOC) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOC and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.81B, about 1996.9x BIOC ($45.5M).
- ELV has hit the wire 3 times in the past 4 weeks while BIOC has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 0 for BIOC).
- Company
- Biocept Inc.
- Elevance Health Inc.
- Price
- $0.41-20.43%
- $418.31+0.63%
- Market cap
- $45.5M
- $90.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 23
Biocept Inc.
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest BIOC
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Biocept Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Why Netflix Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)